{"id":"vaxigrip","safety":{"commonSideEffects":[{"rate":"10–40","effect":"Injection site reactions (pain, redness, swelling)"},{"rate":"5–15","effect":"Myalgia"},{"rate":"5–10","effect":"Headache"},{"rate":"1–5","effect":"Fever"},{"rate":"5–10","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated (killed) influenza virus antigens from three or four seasonal strains, which trigger both humoral and cellular immune responses without causing infection. Upon vaccination, the body produces specific antibodies and memory immune cells that recognize and neutralize circulating influenza viruses, providing protection against seasonal flu infection and reducing disease severity.","oneSentence":"Vaxigrip is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:14:52.355Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults and children"}]},"trialDetails":[{"nctId":"NCT06716567","phase":"PHASE4","title":"Maternal Determinants of Immunity to Influenza","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Saint Pierre","startDate":"2020-11-16","conditions":"Vaccination; Infection, Maternal-Fetal Relations, Influenza","enrollment":109},{"nctId":"NCT00386542","phase":"PHASE1, PHASE2","title":"Needle-free Jet Injection of Reduced-dose, Intradermal, Influenza Vaccine in >= 6 to < 24-month-old Children","status":"COMPLETED","sponsor":"Pedro Moro","startDate":"2006-10","conditions":"Influenza","enrollment":450},{"nctId":"NCT03777163","phase":"PHASE4","title":"Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2019-04-22","conditions":"Influenza","enrollment":632},{"nctId":"NCT02957890","phase":"PHASE4","title":"Immunogenicity of Twice-annual Influenza Vaccination in Older Adults in Hong Kong","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2016-11-18","conditions":"Influenza, Human","enrollment":400},{"nctId":"NCT04523324","phase":"PHASE4","title":"Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2019-10-31","conditions":"Influenza","enrollment":577},{"nctId":"NCT05470582","phase":"PHASE3","title":"Trial of Tolerability, Safety and Immunogenicity of the Flu-M Vaccine in Children Between 6 Months and 9 Years Old","status":"COMPLETED","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2021-02-16","conditions":"Influenza, Human, Vaccination; Infection, Vaccines","enrollment":1066},{"nctId":"NCT05297994","phase":"PHASE2","title":"Trial of the Reactogenicity, Safety and Immunogenicity of the Flu-M Vaccine Manufactured by FSUE SPbSRIVS FMBA","status":"COMPLETED","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2016-10-24","conditions":"Influenza","enrollment":400},{"nctId":"NCT00880893","phase":"PHASE2","title":"Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-04-07","conditions":"Dengue Fever, Dengue Hemorrhagic Fever, Dengue Virus","enrollment":1198},{"nctId":"NCT01034254","phase":"PHASE3","title":"Field Trial of Maternal Influenza Immunization in Asia","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2010-11","conditions":"Influenza Human","enrollment":3693},{"nctId":"NCT02645032","phase":"PHASE1","title":"Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2016-05-19","conditions":"Typhoid","enrollment":144},{"nctId":"NCT01215669","phase":"PHASE4","title":"Study of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-10","conditions":"Influenza","enrollment":240},{"nctId":"NCT00778895","phase":"PHASE2","title":"Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-11-10","conditions":"Influenza","enrollment":390},{"nctId":"NCT03266237","phase":"PHASE4","title":"The Immune Response to Influenza Vaccinations in Elderly Individuals","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2013-12","conditions":"Influenza","enrollment":240},{"nctId":"NCT01665807","phase":"PHASE4","title":"A Time-motion Study Comparing Self- to Nurse-vaccination With Influenza Vaccine","status":"COMPLETED","sponsor":"Brenda Coleman","startDate":"2012-09","conditions":"Influenza, Vaccination Site Reactions (HT)","enrollment":868},{"nctId":"NCT02640989","phase":"PHASE4","title":"Safety and Immunogenicity of Three Seasonal Trivalent Influenza Vaccines in China Military","status":"COMPLETED","sponsor":"Center for Disease Prevention and Control of Beijing Military Region","startDate":"2014-10","conditions":"Influenza","enrollment":292},{"nctId":"NCT00776438","phase":"PHASE2","title":"Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-09","conditions":"Influenza, Orthomyxovirus Infections, Myxovirus Infection","enrollment":160},{"nctId":"NCT00792051","phase":"NA","title":"Direct and Indirect Benefits of Influenza Vaccine Versus Placebo in Healthy Children","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2008-09","conditions":"Influenza Virus Infection","enrollment":2800},{"nctId":"NCT01916759","phase":"NA","title":"Differences in Response to the Flu Vaccine Among Adults With HIV and Without HIV in Uganda","status":"COMPLETED","sponsor":"Emory University","startDate":"2013-06","conditions":"HIV, Acquired Immunodeficiency Syndrome, Influenza","enrollment":63},{"nctId":"NCT00383526","phase":"PHASE3","title":"Study of Inactivated, Split-Virion Influenza Vaccine Compared With the Reference Vaccine Vaxigrip® in the Elderly","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-09","conditions":"Orthomyxoviridae Infection, Influenza, Myxovirus Infection","enrollment":3707},{"nctId":"NCT00606359","phase":"PHASE2","title":"Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-11","conditions":"Influenza, Orthomyxoviridae Infections","enrollment":62},{"nctId":"NCT00258934","phase":"PHASE2","title":"Immunogenicity Study of the Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2005-09","conditions":"Orthomyxoviridae Infections, Influenza","enrollment":978},{"nctId":"NCT00703651","phase":"PHASE2","title":"Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2003-09","conditions":"Influenza, Orthomyxoviridae Infection, Myxovirus Infection","enrollment":1150},{"nctId":"NCT01707602","phase":"PHASE1, PHASE2","title":"Routes of Immunization and Flu Immune Responses","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-10","conditions":"Influenza","enrollment":60},{"nctId":"NCT00710866","phase":"PHASE3","title":"Influenza Vaccine Dose-Response in Infants and Toddlers: Immunogenicity and Reactogenicity","status":"COMPLETED","sponsor":"British Columbia Centre for Disease Control","startDate":"2008-08","conditions":"Influenza","enrollment":262},{"nctId":"NCT00776750","phase":"PHASE4","title":"Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2003-09","conditions":"Hemodialysis, Renal Transplantation","enrollment":407}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":109,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vaxigrip, intramuscular trivalent influenza vaccine"],"phase":"marketed","status":"active","brandName":"Vaxigrip®","genericName":"Vaxigrip®","companyName":"National University Hospital, Singapore","companyId":"national-university-hospital-singapore","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vaxigrip is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains. Used for Seasonal influenza prevention in adults and children.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}